Mr. Weaver joined Altimmune as Chief Financial Officer in November 2024. He has over 25 years of finance experience across a range of publicly-traded and privately-held life sciences companies. Most recently, he was CFO of Cognito Therapeutics, a clinical-stage company targeting neurodegenerative diseases. Prior to joining Cognito, he was CFO at atai Life Sciences (Nasdaq: ATAI), a neuropsychiatry company where he led a $225 million Initial Public Offering in 2021. Throughout his career, Mr. Weaver has led multiple capital markets transactions, manufacturing and R&D investments, product launches and M&A transactions.
He has led the finance, SEC reporting and investor relations functions as CFO of multiple publicly-traded biotech companies including Sirna Therapeutics (Nasdaq: RNAI), a genetic medicines company acquired by Merck and ILEX Oncology (Nasdaq: ILXO), a commercial-stage company acquired by Genzyme.
He currently serves as a Director and Chair of the Audit Committee at BioIntelliSense, a commercial-stage patient monitoring technology company and as Vice-Chairman of the Board at HarborPath, a non-profit organization focused on providing patients with access to life-saving medications. A United States Air Force veteran, he holds a bachelor’s degree in Accounting and Finance from Trinity University and an MBA from Boston College.
